Daily Intelligence for Biotech Investors

The deal tapeserious biotech investors actually read

Top news, M&A, BD&L, IPOs, and VC financings — distilled to a 5-minute read every market morning. No hype. No filler. Just the signal.

Trusted by 2,000+ biotech execs, VCs, BD leads, public market investors - free

Latest Editions

Daily

Sep 8

Tuesday: Novartis drops 10% on its 2nd Phase 3 flop

Novo scraps two more ziltivekimab trials, and FDA approves a drug off a blood test.

Sep 4

Friday: Ionis lands a first, GSK pays $110M for a pre-IND molecule

An ultra-rare approval, a 74% response rate, and a licence signed before Phase 1.

Sep 3

Thursday: Ultragenyx drops 44% after the bell

A clean Phase 3 miss, an FDA warning shot, and $3.22B for a better needle.

Sep 2

Wednesday: Novartis wins in MS, Alumis drops 54%

Two Phase 3 wins for a BTK pill, and Roche writes another China check.

Sep 1

Tuesday: 3 deaths freeze CAR-T, 9 more names sign MFN

Class-wide safety scare, a 26-name pricing club, and ARCH goes shopping for $3B.

2,000+

Subscribers

5×

Issues per week

16+

Research reports

~$194.1B

M&A tracked YTD

Research Hub

Live trackers & research

Live Trackers

Biotech M&A Tracker 2026

Every control transaction in 2026 — target, acquirer, deal value, premium-to-unaffected, and investor-grade rationale. 67 deals. ~$194.1B tracked.

Last updated 7 September 2026

Biotech BD&L Tracker 2026

Licensing and partnering deals — upfronts, milestones, royalties, territory rights, and a one-line why it matters. 130 deals. Up to US$18.5B largest package.

Last updated 7 September 2026

Biotech IPO Tracker 2026

Every biotech IPO this year — pricing date, proceeds, valuation at pricing, and aftermarket performance. 21 deals. ~$6.5B tracked.

Last updated 7 September 2026

Biotech Venture Funding Tracker 2026

VC and crossover rounds — company, stage, lead investors, therapeutic area, and what they are building. 161 deals. US$2.1B largest round.

Last updated 7 September 2026

Research

Most Active Biotech Investors 2026

Ranked league table of the most active biotech and biopharma investors in 2026 by qualifying deal participation.

Top 50 Biotech Investors in Europe 2026

Every leading biotech investor in the UK and EU — headquarters, investor type, stage focus and why they matter. 50 investors mapped across 11 countries.

Biotech Conference Calendar 2026

Major biotech and biopharma conferences in 2026 across the US, UK, and EU, including investor events, scientific catalysts, and partnering meetings.

Top 10 BioPharma M&A Deals of 2025

Ranked list of the 10 biggest biopharma and biotech acquisitions announced in 2025, with stage, therapeutic area, and investor-grade read-through.

Biotech M&A H1 2026 Report

49 deals, ~$149B in value. Q2 nearly doubled Q1. Five $10B+ takeouts, all in Q2. Lilly signed 11 deals.

Biotech M&A Q1 2026 Report

16 deals, $44B in value, and what the deal tape signals about where strategic buyers are paying up.

2024 Biopharma M&A: Every $1B+ Deal

The complete list of 2024 biopharma acquisitions worth $1B or more — public and private targets.

Biotech Funding Terms Glossary

Plain-English definitions of the deal terms that appear in press releases, term sheets, IPOs, and M&A announcements.

About BioBucks

BioBucks is a daily newsletter for biotech and biopharma investors — covering M&A, BD&L deals, IPOs, venture rounds, and catalyst-driven market moves, with the framing that institutional dealmakers actually care about.

Every edition is written to be read in under 5 minutes, with the why it matters front and centre. No press release regurgitation. No noise.

Alongside the daily tape, the Research Hub provides live trackers and standalone reports that serve as reference tools for the community.

Who reads BioBucks

VC / GrowthBiotech venture investors tracking the deal environment

BD&LBusiness development professionals monitoring partnerships

Public MarketsBuyside analysts and portfolio managers

FoundersBiotech CEOs watching comps and M&A premiums